Chemomab Sets Single-Phase 3 Path With FDA After Strong 2025 Nebokitug Data

Chemomab Therapeutics ( (CMMB) ) has provided an announcement.

On March 19, 2026, Chemomab Therapeutics reported its year-end and fourth quarter 2025 results, highlighting 2025 as a pivotal year marked by positive Phase 2 SPRING trial data for nebokitug in primary sclerosing cholangitis and a successful FDA End-of-Phase 2 meeting that aligned on a streamlined pathway to potential approval via a single Phase 3 registration trial. Throughout 2025 the company broadened nebokitug’s scientific and clinical profile through multiple high-visibility conference presentations, a peer-reviewed publication, expanded global patent coverage, and World Health Organization naming, while also strengthening its development leadership team and adjusting its ADS ratio as it advanced partnering discussions and prepared for Phase 3 initiation.

The SPRING trial data presented at major liver and gastroenterology meetings and in leading journals showed nebokitug to be generally safe and well tolerated, with consistent improvements in inflammatory and fibrotic biomarkers and mechanistic evidence supporting its disease-modifying potential in PSC. Additional regulatory milestones, including FDA agreement on Chemistry, Manufacturing and Controls and flexibility on certain toxicology requirements, alongside new patents in China and Russia and recognition such as “posters of distinction” and best oral presentation awards, reinforced Chemomab’s scientific credibility and positioned the company as an emerging leader in PSC and broader fibro-inflammatory disease therapeutics.

The most recent analyst rating on (CMMB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.

Spark’s Take on CMMB Stock

According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.

The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn with shrinking equity) and very bearish technical conditions (below all major moving averages with negative MACD). Valuation provides little support due to negative earnings and no dividend yield data.

To see Spark’s full report on CMMB stock, click here.

More about Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company based in Tel Aviv and listed on Nasdaq under the ticker CMMB. The company develops innovative therapeutics for fibro-inflammatory diseases with high unmet medical need, led by nebokitug, a first-in-class antibody targeting the soluble protein CCL24, with a primary focus on primary sclerosing cholangitis and potential expansion into other fibrotic indications.

Average Trading Volume: 83,181

Technical Sentiment Signal: Sell

Current Market Cap: $12.31M

For detailed information about CMMB stock, go to TipRanks’ Stock Analysis page.